Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
BoFA says Novo Nordisk may miss Q1 expectations as Wegovy, Ozempic sales lag
08:41am, Friday, 28'th Mar 2025
Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy and Ozempic drugs lag, which could prompt the Danish drugmaker to cut its 2
Novo Nordisk should steady nerves by restating growth targets alongside Q1 results
08:26am, Friday, 28'th Mar 2025
JP Morgan expects Novo Nordisk (NYSE:NVO) to hold the line on its 2025 growth targets when it reports first-quarter results, saying a reaffirmation of guidance would help calm nerves after a sluggish
Lexicon to license obesity drug to Novo Nordisk in up to $1 billion deal
07:41am, Friday, 28'th Mar 2025
Lexicon Pharmaceuticals said on Friday it has entered into an agreement with Novo Nordisk to license its non-incretin-based experimental obesity drug for up to $1 billion.
Why Novo Nordisk Stock Dipped on Thursday
06:36pm, Thursday, 27'th Mar 2025
Novo Nordisk's (NVO -2.13%) is famous and celebrated for its cutting-edge obesity medication. But on Thursday, its stock felt like the company ingested some of its own treatment.
Novo Nordisk says copycat compounders are hurting Wegovy sales, may take legal action
01:46pm, Thursday, 27'th Mar 2025
Obesity drug giant Novo Nordisk said Thursday that the rampant growth of the U.S.'s compounded drug industry was hurting Wegovy sales. CEO Lars Fruergaard Jørgensen told shareholders at its Annual Ge
Novo shares on track for biggest monthly fall since 2002, investor worries grow
01:29pm, Thursday, 27'th Mar 2025
Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as investor worries intensify that the obesity drug market pioneer has lost its edg
Resolutions from the Annual General Meeting of Novo Nordisk A/S
11:17am, Thursday, 27'th Mar 2025
Bagsværd, Denmark, 27 March 2025 - Today, Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Helge Lund, chair of the Board of Directors communicated: “2024 was anoth
1 Growth Stock Down 40% to Buy and Hold Forever
10:00am, Thursday, 27'th Mar 2025
This might surprise some, but Danish pharmaceutical giant Novo Nordisk (NVO -2.29%) has significantly lagged the market in the past year. The drugmaker's shares are down by 40% over the trailing-12-mo
Checking in on the weight-loss drug space: Novo Nordisk, Eli Lilly, and others
05:58pm, Wednesday, 26'th Mar 2025
Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could be pivotal for the obesity treatment market due to its accessibility.
Novo Nordisk Stock Sinks To 52-Week Lows: Weight Loss Boom Losing Steam?
02:01pm, Wednesday, 26'th Mar 2025
Novo Nordisk A/S NVO has been on a tear in the weight loss drug race, but its stock is slimming down for all the wrong reasons.
Buy Low, Never Sell - 2 Elite Dividend Stocks Built To Last
07:30am, Wednesday, 26'th Mar 2025
Markets are rotating away from U.S. stocks, but I'm doubling down on undervalued American companies built to last decades, not chase trends. Political noise and short-term trading dominate headlines,
Is Novo Nordisk Stock a Buy?
05:13am, Wednesday, 26'th Mar 2025
There is a long-running health crisis impacting the modern world. According to the World Health Organization, one in eight people worldwide were living with obesity as of 2022.
Class Action Filed Against Novo Nordisk A/S (NVO) - March 25, 2025 Deadline to Join - Contact Levi & Korsinsky
04:30pm, Tuesday, 25'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws,
Investors who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
01:30pm, Tuesday, 25'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws,
Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%
01:05pm, Tuesday, 25'th Mar 2025
NVO's shares are down 2% despite making Wegovy available at a discounted price of $499 per month at local pharmacies.
